What is the price targets for Protagenic Therapeutics'stock?
Their forecasts range from $4.00 to $4.00. On average, they anticipate Protagenic Therapeutics' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 175.9% from the stock's current price. View analysts' price targets for Protagenic Therapeutics or view top-rated stocks among Wall Street analysts.
What is the symbol for ptix stock?
In connection with the offering, the Company has received approval to list its common stock and warrants on the Nasdaq Capital Market, with its common stock trading under the symbol “PTIX” and the warrants trading under the symbol “PTIXW”, with trading expected to begin on April 27, 2021.
Is Protagenic Therapeutics (PRT) a good buy with a negative PE ratio?
Only 1.41% of the stock of Protagenic Therapeutics is held by institutions. The P/E ratio of Protagenic Therapeutics is -4.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Will PRZIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
A leadership transition well carried out
This strategy, which includes T. Rowe Price Emerging Markets Stock, its two U.S.-sold institutional and CIT versions, and its UCITS twin, is going through a manager transition. Its longtime skipper Gonzalo Pangaro will retire in January 2022.
What is the P/E ratio of Protagenic Therapeutics?
The P/E ratio of Protagenic Therapeutics is -4.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Where is Protagenic Therapeutics located?
Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at (212) 994-8200, via email at [email protected], or via fax at 603-761-6223.
Is Protagenic Therapeutics a buy?
Protagenic Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Does Protagenic Therapeutics pay dividends?
Protagenic Therapeutics does not currently pay a dividend.
When is PTIX 2021?
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET. The webinar will feature a presentation by Dr. Maurizio Fava, Psychiatrist-in-Chief in the Depar
What is Protagenic Therapeutics?
is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat anxiety, treatment-resistant depression, addiction, and other disorders.
What is PT00114?
Moreover, PT00114 is being developed as a therapeutic for anxiety, depression, post-traumatic stress disorder (PTSD) and addiction, each of which have been shown to be associated with impaired glucose metabolism in the brain.
Who is Brookline Capital Markets?
Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-manager. The Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 relating to these securities on April 26, 2021. A final prospectus relating to this offering was filed with the SEC.
Is PT00114 a first class compound?
PT00114 is a first-in-class compound , and has demonstrated compelling efficacy potential with a strong safety profile in extensive preclinical models.“PT00114 has a unique mechanism of action, with robust effects in preclinical studies.
